+91
By proceeding, you agree to all T&C*
Didn't receive the code? Resend
544759 GOLDLINE

Goldline Pharmaceutical Share Price

 

 

Goldline Pharmaceutical live price: ₹42.23. It opened at ₹42 vs previous close ₹42; intraday high/low: ₹42/₹42.

Goldline Pharmaceutical Performance

  • Today's Low
  • ₹42
  • Today's High
  • ₹42
  • 52 Week Low
  • ₹41
  • 52 Week High
  • ₹60
  • Open Price₹42
  • Previous Close₹42
  • Volume6,000
  • 50 DMA-
  • 100 DMA-
  • 200 DMA-

Goldline Pharmaceutical Chart

Investment Returns

  • Over 1 Month -8.26%

Smart Investing Starts Here Start SIP with Goldline Pharmaceutical for Steady Growth!

Invest Now

Goldline Pharmaceutical Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 9.8
  • PEG Ratio
  • -
  • Market Cap Cr
  • 41
  • P/B Ratio
  • 3.1
  • Average True Range
  • 2.37
  • EPS
  • -
  • Dividend Yield
  • 0
  • MACD Signal
  • -
  • RSI
  • 35.02
  • MFI
  • 32.13

Goldline Pharmaceutical Financials

Goldline Pharmaceutical Technicals

EMA & SMA

Current Price
₹42.23
-0.06 (-0.14%)
pointer
  • Bearish Moving Average 9
  • Bullish Moving Average 0
  • 20 Day
  • ₹44.50
  • 50 Day
  • -
  • 100 Day
  • -
  • 200 Day
  • -

Resistance and Support

42.23 Pivot Speed
  • R3 42.23
  • R2 42.23
  • R1 42.23
  • S1 42.23
  • S2 42.23
  • S3 42.23

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

N/A

Group Rank

Goldline Pharmaceuticals markets 146 pharmaceutical products across five divisions, including Goldline Pharma, Cardinal, Aayushman, InLife, and Wellness. The company operates in 7 Indian states through 15 manufacturing partners and 7 distributors, serving specialties such as cardiology, pediatrics, orthopedics, oncology, and critical care.

Goldline Pharmaceutical Ltd has an operating revenue of Rs. 82.82 Cr. on a trailing 12-month basis. An annual revenue growth of 11% is good, Pre-tax margin of 17% is great, ROE of 33% is exceptional. The company has a reasonable debt to equity of 12%, which signals a healthy balance sheet. From an O'Neil Methodology perspective, the stock has an EPS Rank of 72 which is a FAIR score but needs to improve its earnings, a RS Rating of 7 which is POOR indicating the underperformance as compared to other stocks, Group Rank of 29 indicates it belongs to a strong industry group of Medical-Biomed/Biotech and a Master Score of D is close to being the worst. Overall, the stock has mediocre earnings and technical strength, there are superior stocks in the current market environment. Please note that this is a thinly traded stock.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Goldline Pharmaceutical Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2026-06-09 Audited Results

Goldline Pharmaceutical Shareholding Pattern

57.29%
5.16%
0.09%
25.14%
12.32%

Goldline Pharmaceutical FAQs

Goldline Pharmaceutical share price is ₹42 As on 03 July, 2026 | 00:24

The Market Cap of Goldline Pharmaceutical is ₹40.5 Cr As on 03 July, 2026 | 00:24

The P/E ratio of Goldline Pharmaceutical is 9.8 As on 03 July, 2026 | 00:24

The PB ratio of Goldline Pharmaceutical is 3.1 As on 03 July, 2026 | 00:24

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23